WO2002010770A3 - Improved methods for identifying reagents which inhibit tau polymerization - Google Patents

Improved methods for identifying reagents which inhibit tau polymerization Download PDF

Info

Publication number
WO2002010770A3
WO2002010770A3 PCT/US2001/041512 US0141512W WO0210770A3 WO 2002010770 A3 WO2002010770 A3 WO 2002010770A3 US 0141512 W US0141512 W US 0141512W WO 0210770 A3 WO0210770 A3 WO 0210770A3
Authority
WO
WIPO (PCT)
Prior art keywords
polymerization
improved methods
current invention
tau
provides
Prior art date
Application number
PCT/US2001/041512
Other languages
French (fr)
Other versions
WO2002010770A2 (en
Inventor
T Chris Gamblin
Lester I Binder
Original Assignee
Neuronautics Inc
T Chris Gamblin
Lester I Binder
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuronautics Inc, T Chris Gamblin, Lester I Binder filed Critical Neuronautics Inc
Priority to AU2001283528A priority Critical patent/AU2001283528A1/en
Publication of WO2002010770A2 publication Critical patent/WO2002010770A2/en
Publication of WO2002010770A3 publication Critical patent/WO2002010770A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The current invention provides novel methods for stimulating the polymerization of tau protein by altering oxidative conditions for the polymerization reaction and/or by altering the oxidative state of a fatty acid used to stimulate the polymerization reaction. The current invention provides a method for screening reagents for the ability to effect tau polymerization using the novel methods of the invention for inducing tau polymerization. Finally, the current invention provides methods for regulating the assembly of tau protein in the brain of mammals in need of such regulation, by administering to the mammal, an effect amount of an inhibitor of fatty acid oxidation.
PCT/US2001/041512 2000-07-31 2001-07-31 Improved methods for identifying reagents which inhibit tau polymerization WO2002010770A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001283528A AU2001283528A1 (en) 2000-07-31 2001-07-31 Improved methods for identifying reagents which inhibit tau polymerization

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22177700P 2000-07-31 2000-07-31
US60/221,777 2000-07-31

Publications (2)

Publication Number Publication Date
WO2002010770A2 WO2002010770A2 (en) 2002-02-07
WO2002010770A3 true WO2002010770A3 (en) 2003-04-03

Family

ID=22829342

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/041512 WO2002010770A2 (en) 2000-07-31 2001-07-31 Improved methods for identifying reagents which inhibit tau polymerization

Country Status (2)

Country Link
AU (1) AU2001283528A1 (en)
WO (1) WO2002010770A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2264841B1 (en) * 2003-12-17 2008-01-01 Consejo Sup. Investig. Cientificas PROCEDURE FOR THE IDENTIFICATION OF INHIBITING COMPOUNDS OF THE TAU PROTEIN ASSEMBLY PROCESS AND ITS APPLICATIONS.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192753A (en) * 1991-04-23 1993-03-09 Mcgeer Patrick L Anti-rheumatoid arthritic drugs in the treatment of dementia
WO1995000130A1 (en) * 1993-06-28 1995-01-05 The Howard Foundation Use of hydrophilic carotenoids for the manufacture of a medicament for the treatment of diseases having an oxygenation mechanism
WO1997005780A1 (en) * 1995-08-08 1997-02-20 The University Of Alabama At Birmingham Research Foundation Regulation of alzheimer's disease related proteins and uses thereof
WO1998052560A1 (en) * 1997-05-21 1998-11-26 Sloan-Kettering Institute For Cancer Research Method for increasing the concentration of ascorbic acid in brain tissues of a subject

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192753A (en) * 1991-04-23 1993-03-09 Mcgeer Patrick L Anti-rheumatoid arthritic drugs in the treatment of dementia
WO1995000130A1 (en) * 1993-06-28 1995-01-05 The Howard Foundation Use of hydrophilic carotenoids for the manufacture of a medicament for the treatment of diseases having an oxygenation mechanism
WO1997005780A1 (en) * 1995-08-08 1997-02-20 The University Of Alabama At Birmingham Research Foundation Regulation of alzheimer's disease related proteins and uses thereof
WO1998052560A1 (en) * 1997-05-21 1998-11-26 Sloan-Kettering Institute For Cancer Research Method for increasing the concentration of ascorbic acid in brain tissues of a subject

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GAMBLIN T C ET AL: "Oxidative regulation of fatty acid-induced tau polymerization.", BIOCHEMISTRY. UNITED STATES 21 NOV 2000, vol. 39, no. 46, 21 November 2000 (2000-11-21), pages 14203 - 14210, XP002202929, ISSN: 0006-2960 *
MITCHELL J A ET AL: "CYCLO-OXYGENASE-2: PHARMACOLOGY, PHYSIOLOGY, BIOCHEMISTRY AND RELEVANCE TO NSAID THERAPY", BRITISH JOURNAL OF PHARMACOLOGY, BASINGSTOKE, HANTS, GB, vol. 128, no. 6, 1999, pages 1121 - 1132, XP001031817, ISSN: 0007-1188 *
WILSON D M ET AL: "FREE FATTY ACIDS STIMULATE THE POLYMERIZATION OF TAU AND AMYLOID BETA PEPTIDES IN VITRO EVIDENCE FOR A COMMON EFFECTOR OF PATHOGENESIS IN ALZHEIMER'S DISEASE", AMERICAN JOURNAL OF PATHOLOGY, PHILADELPHIA, PA, US, vol. 150, no. 6, 6 June 1997 (1997-06-06), pages 2181 - 2195, XP000952986, ISSN: 0002-9440 *

Also Published As

Publication number Publication date
AU2001283528A1 (en) 2002-02-13
WO2002010770A2 (en) 2002-02-07

Similar Documents

Publication Publication Date Title
WO2001079464A3 (en) Nucleic acids encoding polypeptides having haloperoxidase activity
WO2001082917A3 (en) Treatment of hypertriglyceridemia and other conditions using lxr modulators
WO2001092308A3 (en) Cystine-knot polypeptides: cloaked-2 molecules and uses thereof
WO2003046146A3 (en) Compositions and methods of selective nucleic acid isolation
WO2005003766A3 (en) Methods of regulating metabolism and mitochondrial function
MXJL03000001A (en) Ion channel assay methods.
WO2000023571A3 (en) A method for isolating and purifying oligodendrocytes and oligodendrocyte progenitor cells
DE69836229D1 (en) COMPOSITIONS OF LOW-VOLUME-ACTIVATED CALCIUM CHANNELS AND METHOD
AU8881201A (en) Tnf receptor-like molecules and uses thereof
WO2004053059A3 (en) Mitoneet polypeptide from mitochondrial membranes, modulators thereof, and methods of using the same
Eraković et al. Electroconvulsive shock in rats: changes in superoxide dismutase and glutathione peroxidase activity
WO2004070025A3 (en) Novel goodpasture antigen-binding protein isoforms and protein misfolded-mediated disorders
WO2002010770A3 (en) Improved methods for identifying reagents which inhibit tau polymerization
WO2001040519A8 (en) Methods for identifying modulators for balance related disorders
WO2002066045A3 (en) Methods for modulating an immune response by modulating the interaction between ctla4 and pp2a
MXPA03000979A (en) C3b/C4b COMPLEMENT RECEPTOR-LIKE MOLECULES AND USES THEREOF.
WO2004039334A3 (en) CALCIUM-SENSING RECEPTOR 2 (CaR2) AND METHODS FOR USING
WO2003070965A8 (en) The eaat2 promoter and uses thereof
WO2002097046A3 (en) B7 related protein-2 molecules and uses thereof
WO2003020887A3 (en) Gene identification
WO1996029407A3 (en) Cellubrevin homologs
AU4654097A (en) Rdgb-proteins
WO2002036166A8 (en) Compositions for stimulating cd45 and thereby suppressing microglial activation associated with alzheimer's disease
WO2003062448A3 (en) Sqv nucleic acids and polypeptides
TW200514775A (en) Methods for the preparation of {2-[(8,9)-dioxo-2,6-diaza-bicyclo[5.2.0]-non-1(7)-en-2-yl]ethyl} phosphonic acid and esters thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 69(1) EPC (EPO FORM 1205A DATED 23.05.03)

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHT PURSUANT TO RULE 69(1) EPC (EPO FORM 1205A DATED 23.05.2003)

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP